 |
|
|
| |
Hepatitis, HCV, HBV & Fatty Liver at CROI 2020
|
| |
| |
150 CROI NATAP reports: ART studies, new HIV drugs, long-acting HIV therapy, 2-drug ART follow-up studies: doluthreavir/3TC, comorbidities/aging/fat/weight/metabolics/diabetes/frailty/brain-neurologic, PrEP, cure, ART drug resistance, low-level viremia & comorbidities-outcomes.
Conference on Retroviruses and Opportunistic Infections
Boston USA
March 8-11, 2020
EASL: Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany
CROI: HEPATITIS C VIRUS INFECTION AND COINFECTION WITH HIV AMONG PWID IN 10 US CITIES (04/02/20)
62.4% (3239/5,190) had a reactive anti-HCV result, 44.2% (1678/3795) had HCV RNA detected, and 4.0% (153/3,779) had HIV/HCV co-infection. Of those with both antibody and RNA test results, 3.9% (149/3795) had acute and 40.3% (1529/3795) had chronic HCV infection. Acute infection was highest among PWID who were male (4.3%), ages 25-34 (4.2%), black (4.5%), HIV-positive (4.6%), injecting 5 years (4.3%), injected >1 time/day (4.2%), injected heroin most often (4.3%), and were from Miami (17.6%) or Philadelphia (5.3%).
—————
NEW UPDATES:
Baby Boomers & Blacks Dominate the Story: - (04/28/20)
NYS New Cases HCV Report 2017/ Here the story is young white injectors & HCC Death Rates Still High - (04/28/20)
U.S. Food And Drug Administration Approves Epclusa (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection - (04/13/20)
CROI: INDIVIDUAL AND POPULATION-LEVEL IMPACT OF HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS (04/10/20)
Probability of cirrhosis declined from 2015 to 2018 from about 17% to about 7%, PWIDs Baltimore ALIVE Cohort due to DAAs. For every year since DAA treatment the odds of cirrhosis decreased by 56%. PLWH had higher rates of cirrhosis & those with higher HIV viral loads had higher rates of cirrhosis-these also had the higher log mean liver stiffness.
CROI: LARGE HEPATITIS C TRANSMISSION CLUSTER IDENTIFIED AMONG HIV POSITIVE MSM IN BANGKOK (04/10/20)
--------------------------
Barriers To Direct-Acting Antiviral Therapy Among HIV/HCV-Coinfected Adults
CROI: Falling Cirrhosis and HCV Viremia in Baltimore PWID, Maybe Reflecting DAAs - (03/11/20) falling cirrhosis rates by 56% since receipt of treatment along with similar decline in over stiffness
http://www.croiwebcasts.org/console/player/44802?mediaType=slideVideo&
CROI: Real-world effectiveness of Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection (03/18/20)
U.S. Food And Drug Administration Approves Epclusa (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection - (03/23/20)
CROI: Real-world effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C Virus Infection (03/18/20)
CROI: HCV Retreatment, Multiple DAA Failures - Case Study (03/18/20)
http://www.croiwebcasts.org/console/player/44545?mediaType=slideVideo&
CROI: Risk of Hepatocellular Carcinoma among Persons Living with HIV and Viral Hepatitis Coinfection in the United States and Canada, 1996-2015 (03/18/20)
CROI: Liver Cancer Rate Rising Since 1996 in North Americans With HIV - (03/18/20)
CROI: NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE - (03/11/20)
CROI: HCV Prevalence Almost 2% in New Mothers in 2 New York State Regions - (03/11/20)
CROI: Six-Week SOF/VEL Inferior to 12 Weeks for Recently Acquired HCV - (03/18/20)
CROI: Progress and Real-Life Challenges for HCV Elimination in People Living with HIV (03/18/20)
CROI: CAUSES OF DEATH IN PERSONS WITH AND WITHOUT HCV INFECTION (03/18/20)
CROI: A Multicenter Registry in HIV/HCV Co-infected Patients Initiating Ledipasvir/Sofosbuvir (03/18/20) Switching ART regimen
CROI: HBV New Agents (04/02/20)
CROI: HCV REINFECTION AFTER DAA TREATMENT AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO (04/02/20)
CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID (03/31/20) India
CROI: Hepatitis C Coinfection and Extrahepatic Cancer Incidence among People with HIV (03/30/20)
CROI: Hepatic Fibrosis Determined with MRE Significantly Predicts Cognitive Impairment (03/30/20)
CROI: SEX, NOT DRUG USE, IS DRIVING HCV RE-INFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY (03/30/20)
CROI: HPTN 078: HIGH INCIDENCE OF HEPATITIS C VIRUS INFECTIONS AMONG MSM (04/02/20)
CROI: HCV INCIDENCE AMONG HIV-INFECTED MSM IN FRANCE: RESULTS FROM THE FHDH-ANRS CO4 COHORT (04/04/20)
CROI: HCV TRANSMISSION AMONG MSM: EXTERNAL INTRODUCTIONS COULD COMPLICATE MICRO-ELIMINATION (04/02/20)
CROI: HEPATITIS C VIRUS INFECTION AND COINFECTION WITH HIV AMONG PWID IN 10 US CITIES (04/02/20)
CROI: Mobile HCV Screening in At-Risk Urban Population Identifies Significant Fibrosis (04/02/20)
CROI: HCV, Opioid Use, Psych Illness Cluster in Veterans Group--Treatment of Opioid Use Very Low (03/30/20)
CROI: BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS (03/23/20)
Fatty Liver / NASH
CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
CROI: INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20)
CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/23/20)
CROI: Fibrosis Progression Over 6-Fold Higher in NAFLD With vs Without HIV - (03/23/20)
CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/23/20)
Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease - (02/28/20)
|
| |
|
|
|
|
|
